「pharma」の検索結果

Think and work like an expert Electrophysiologist. Use when a task calls for Electrophysiologist judgment. Reasons from membrane voltage, conductance kinetics, series resistance, and filter settings through pClamp/Multiclamp acquisition, pharmacological channel isolation (TTX, NBQX/APV, picrotoxin), Hodgkin-Huxley/Markov gating fits, and NWB-standardized reporting while treating Rs drift, dialysis run-down, space clamp, and polysynaptic contamination as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Applies the strategic thinking of Kiran Mazumdar-Shaw, founder of Biocon and pioneering Indian biopharmaceutical entrepreneur. Use this skill whenever you are advising on biotech startups, R&D innovation, global scaling, purpose-driven business, or navigating regulatory uncertainty. Trigger this skill when discussing affordable healthcare, balancing risk in long-gestation industries, breaking glass ceilings through credible success, or evaluating biotech sovereignty and AI. Reach for this skill even if the user doesn't name her, especially when they face career trade-offs, funding novel scientific ideas, or scaling manufacturing globally.

日本語の概要は準備中です。原文の説明を表示しています。

Access ClinPGx pharmacogenomics data (successor to PharmGKB). Query gene-drug interactions, CPIC guidelines, allele functions, for precision medicine and genotype-guided dosing decisions.

日本語の概要は準備中です。原文の説明を表示しています。

Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.

日本語の概要は準備中です。原文の説明を表示しています。

Molecular featurization hub with one consistent interface over 100+ featurizers. Fingerprints (ECFP/Morgan, MACCS, atom pair, topological torsion, Avalon, RDKit, ERG), RDKit and Mordred descriptor sets, pharmacophore and 3D shape descriptors, scaffold keys, and pretrained embeddings (ChemBERTa, ChemGPT, MolT5, GIN, Graphormer) through a common transformer API with caching and parallelism. Use this skill to convert SMILES into model-ready feature matrices for QSAR, virtual screening, and molecular ML, and to choose between featurizer families. Also trigger on molfeat, MoleculeTransformer, FPVecTransformer, PretrainedHFTransformer, molfeat model store, or featurizer selection.

日本語の概要は準備中です。原文の説明を表示しています。

Query the FDA's public openFDA APIs for post-market drug data — FAERS adverse-event reports, Drugs@FDA approval and submission history, Structured Product Labels including boxed warnings, the National Drug Code directory, recall enforcement reports, and drug shortages. Use this skill to check what a regulator has already concluded about a molecule or its class, to date an approval and count its efficacy supplements, to read an approved indication or boxed warning, and to score a drug-event pair for disproportionate reporting with PRR, ROR, and chi-squared. Also trigger on openFDA, api.fda.gov, FAERS, Drugs@FDA, SPL, NDC, pharmacovigilance, boxed warning, adverse event report, drug recall, or safety signal.

日本語の概要は準備中です。原文の説明を表示しています。

Turn in vitro potency and animal pharmacokinetics into a defensible human dose projection — the arithmetic that decides whether a compound can reach its target concentration safely. Use this skill for non-compartmental analysis of a concentration-time profile (AUC, Cmax, terminal half-life, clearance, volume of distribution), one- and two-compartment simulation of a dosing regimen, interspecies allometric scaling, human-equivalent dose conversion by body surface area, and the exposure margin between a projected therapeutic concentration and a toxicology no-effect level. Also trigger on non-compartmental analysis, AUC, clearance, volume of distribution, allometric scaling, human equivalent dose, first-in-human, NOAEL, therapeutic index, or exposure margin.

日本語の概要は準備中です。原文の説明を表示しています。

Query the Precision Medicine Knowledge Graph (PrimeKG) for multiscale biological relationships across genes and proteins, drugs, diseases, phenotypes, pathways, biological processes, exposures and anatomy. Use this skill to search entities by name, pull direct neighbours and their evidence types, summarise the local network around a disease, and find direct or two-hop drug-disease connections for repurposing hypotheses. Also trigger on PrimeKG, kg.csv, Harvard Dataverse knowledge graph, disease_protein, drug_protein, indication and contraindication edges, or network pharmacology over a biomedical knowledge graph.

日本語の概要は準備中です。原文の説明を表示しています。

Audit pharmaceutical yield prediction systems and process analytical technology -- evaluate critical process parameter (CPP) to critical quality attribute (CQA) relationships, design space characterization per ICH Q8(R2) Quality by Design, PAT sensor readiness (NIR, Raman.

日本語の概要は準備中です。原文の説明を表示しています。

Audit a pharmaceutical regulatory submission system -- evaluate eCTD backbone assembly and XML validation, CTD module completeness (Modules 1-5), FDA ESG and EMA CESP gateway integration, document authoring and publishing workflows, ICH M4/M8/E3 guideline compliance.

日本語の概要は準備中です。原文の説明を表示しています。

Audit a drug discovery pipeline for operational efficiency and scientific rigor. Triggers: building or reviewing pharma R&D platforms, cheminformatics pipelines, or screening data management systems.

日本語の概要は準備中です。原文の説明を表示しています。

ผู้ช่วยเภสัชกร — drug dictionary (Thai/Generic), interaction matrix, pediatric/geriatric/renal dosing, counseling script สำหรับเภสัชกรที่มีใบประกอบวิชาชีพเท่านั้น

日本語の概要は準備中です。原文の説明を表示しています。

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

日本語の概要は準備中です。原文の説明を表示しています。

Query BindingDB for measured drug-target binding affinities (Ki, Kd, IC50, EC50). Search by target (UniProt ID), compound (SMILES/name), or pathogen. Essential for drug discovery, lead optimization, polypharmacology analysis, and structure-activity relationship (SAR) studies.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating intravenous bisphosphonate or denosumab for adults with hypercalcemia of malignancy compared with no treatment. Use when a clinician asks about first‑line pharmacologic therapy for HCM or when deciding to start antiresorptive agents.

日本語の概要は準備中です。原文の説明を表示しています。

Select the right treatment tier for a child with obesity — behavioural, pharmacologic, or surgical — using the CMAJ 2025 pediatric obesity guideline. Trigger when a clinician asks what to do for a child with obesity, which intervention to start, whether to escalate treatment, or when to consider medication or surgery for pediatric obesity.

日本語の概要は準備中です。原文の説明を表示しています。

Diagnose monogenic and syndromic obesity in children and adolescents using a structured step-by-step algorithm. Use this skill whenever a clinician suspects a genetic cause of obesity, asks about leptin deficiency, MC4R mutation, POMC deficiency, PCSK1 deficiency, leptin receptor deficiency, Bardet-Biedl syndrome, Prader-Willi syndrome, Alström syndrome, or any case of early-onset severe obesity with hyperphagia. Also trigger for questions about targeted pharmacotherapy including setmelanotide or metreleptin, or when to order a genomic obesity panel. Cross-references the NHS Genomic Test Finder skill to surface the relevant R-code once a diagnosis is reached.

日本語の概要は準備中です。原文の説明を表示しています。

中国药品权威数据库查询 — NMPA(国家药监局) + CDE(药品审评中心) + DrugBank(英文名/ATC) + PubChem(化学结构) 多源融合,提供(通用名 ↔ 商品名 ↔ 英文名 ↔ 适应症 ↔ NMPA 批文号 ↔ 上市日期)精确映射。Make sure to use this skill whenever the user mentions 药品名 / 通用名 / 商品名 / NMPA / 国药准字 / 药监局 / CDE / drug brand name / generic name / drug registry / pharmaceutical lookup / drug verification / 药物核验 / 商品名对应 / drug cross-check / drug authority lookup. 在任何 medical / market-sizing / clinical / disease-research 报告生成阶段,**所有药品提及必须先调 lookup_drug() 验证**,严禁 LLM 凭训练记忆拼凑通用名↔商品名↔英文名对应关系。LLM 训练截止后药企会更换商品名、新药持续上市,记忆完全不可信。Iron Law:lookup 返回 None → 调用方必须 raise UnverifiedDrugError,不允许 fallback 到记忆。免费公开数据源,跨平台:Claude Code / Codex / Gemini CLI 三端均可 auto-trigger,实现仅依赖 httpx + beautifulsoup4 标准生态,不绑定任何厂商 SDK。

日本語の概要は準備中です。原文の説明を表示しています。

Expert en biotechnologie (bioinformatics, genomics, CRISPR, clinical trials, FDA)

日本語の概要は準備中です。原文の説明を表示しています。

Solve quantitative problems in biophysics — pharmacokinetics (PK volume of distribution, clearance, half-life), epidemiology (R0, attack rate), toxicology (LD50, NOAEL), population genetics (Hardy-Weinberg, Fst), enzyme kinetics (Michaelis-Menten), thermodynamics. Use for first-principles quantitative biology calculations, dose calculations, exposure assessment, and biophysical-property estimation.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive drug profiling — mechanism, primary/secondary targets, drug interactions, clinical-trial status, adverse events (FAERS), pharmacogenomics, and approval history. Use for full drug investigation reports, 'tell me about drug X' queries, and assembling drug profiles for clinicians, researchers, or regulatory work.

日本語の概要は準備中です。原文の説明を表示しています。

Dose-response / concentration-response curve fitting — IC50, EC50, Hill slope, Emax/Emin efficacy, and relative potency from paired concentration vs response data (enzyme/cell assays, drug screening, agonist/antagonist pharmacology). Fits the 4-parameter logistic (Hill sigmoidal) model. Use when you have concentrations + responses and need a potency value, to compare two compounds' potency, or to judge curve quality. NOT for image-derived dose-response (use tooluniverse-image-analysis) and NOT for survival/regression (use tooluniverse-statistical-modeling).

日本語の概要は準備中です。原文の説明を表示しています。

Therapeutics Data Commons. AI-ready drug discovery datasets (ADME, toxicity, DTI), benchmarks, scaffold splits, molecular oracles, for therapeutic ML and pharmacological prediction.

日本語の概要は準備中です。原文の説明を表示しています。

ADMET property prediction for drug candidates. Full pharmacokinetic panel (Caco-2, PPB, clearance, CYP), toxicity (hERG, AMES, DILI), drug-likeness (Lipinski, QED), using RDKit descriptors and TDC models.

日本語の概要は準備中です。原文の説明を表示しています。